Morgan Stanley’s IGC Pharma IGC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $9.57K | Buy |
35,198
+80
| +0.2% | +$24 | ﹤0.01% | 7057 |
|
|
2026
Q1 | $9.24K | Buy |
35,118
+17,411
| +98% | +$4.83K | ﹤0.01% | 6974 |
|
|
2025
Q4 | $4.98K | Hold |
17,707
| – | – | ﹤0.01% | 7068 |
|
|
2025
Q3 | $7.38K | Hold |
17,707
| – | – | ﹤0.01% | 6983 |
|
|
2025
Q2 | $5.42K | Hold |
17,707
| – | – | ﹤0.01% | 7014 |
|
|
2025
Q1 | $5.05K | Hold |
17,707
| – | – | ﹤0.01% | 6991 |
|
|
2024
Q4 | $5.95K | Sell |
17,707
-50
| -0.3% | -$19 | ﹤0.01% | 6960 |
|
|
2024
Q3 | $7.58K | Buy |
17,757
+16,897
| +1,965% | +$6.77K | ﹤0.01% | 6793 |
|
|
2024
Q2 | $373 | Hold |
860
| – | – | ﹤0.01% | 7253 |
|
|
2024
Q1 | $344 | Hold |
860
| – | – | ﹤0.01% | 7270 |
|
|
2023
Q4 | $241 | Buy |
860
+50
| +6% | +$15 | ﹤0.01% | 7286 |
|
|
2023
Q3 | $291 | Hold |
810
| – | – | ﹤0.01% | 7361 |
|
|
2023
Q2 | $252 | Hold |
810
| – | – | ﹤0.01% | 7435 |
|
|
2023
Q1 | $275 | Hold |
810
| – | – | ﹤0.01% | 7495 |
|
|
2022
Q4 | $258 | Sell |
810
-100
| -11% | -$41 | ﹤0.01% | 7620 |
|
|
2022
Q3 | $0 | Sell |
910
-501
| -36% | -$267 | ﹤0.01% | 7786 |
|
|
2022
Q2 | $1K | Sell |
1,411
-38
| -3% | -$24 | ﹤0.01% | 7683 |
|
|
2022
Q1 | $1K | Buy |
1,449
+39
| +3% | +$38 | ﹤0.01% | 7845 |
|
|
2021
Q4 | $1K | Hold |
1,410
| – | – | ﹤0.01% | 7871 |
|
|
2021
Q3 | $2K | Buy |
1,410
+910
| +182% | +$1.47K | ﹤0.01% | 7666 |
|
|
2021
Q2 | $1K | Hold |
500
| – | – | ﹤0.01% | 7613 |
|
|
2021
Q1 | $1K | Sell |
500
-1,002
| -67% | -$1.82K | ﹤0.01% | 7348 |
|
|
2020
Q4 | $2K | Sell |
1,502
-3,248
| -68% | -$4.8K | ﹤0.01% | 6892 |
|
|
2020
Q3 | $5K | Buy |
4,750
+1,000
| +27% | +$1.02K | ﹤0.01% | 6440 |
|
|
2020
Q2 | $2K | Buy |
3,750
+1,250
| +50% | +$678 | ﹤0.01% | 6448 |
|
|
2020
Q1 | $1K | Hold |
2,500
| – | – | ﹤0.01% | 6462 |
|
|
2019
Q4 | $2K | Sell |
2,500
-76
| -3% | -$62 | ﹤0.01% | 6501 |
|
|
2019
Q3 | $2K | Buy |
2,576
+76
| +3% | +$91 | ﹤0.01% | 6480 |
|
|
2019
Q2 | $4K | Sell |
2,500
-27,650
| -92% | -$39.1K | ﹤0.01% | 6350 |
|
|
2019
Q1 | $63K | Buy |
+30,150
| New | +$68.5K | ﹤0.01% | 5563 |
|
|
2018
Q4 | – | Sell |
-725
| Closed | -$5K | – | 6648 |
|
|
2018
Q3 | $5K | Buy |
+725
| New | +$753 | ﹤0.01% | 6445 |
|
|
2013
Q3 | – | Sell |
-22,294
| Closed | -$35K | – | 5353 |
|
|
2013
Q2 | $35K | Buy |
+22,294
| New | +$46.7K | ﹤0.01% | 5232 |
|
Other funds holding IGC
AI
LC
Morgan Stanley's IGC Position: Q2 2026 in Review
Morgan Stanley increased its IGC Pharma (IGC) stake by 0.23% in Q2 2026, buying an estimated $24 and bringing the position to 35,198 shares worth $9.57K. The position accounts for ﹤0.01% of the portfolio, ranked #7057.
Morgan Stanley first reported a position in IGC in Q2 2013 and has held it in 32 quarters since. The position peaked at $63K in Q1 2019. 36 funds tracked by Wall St. Rank hold IGC as of Q2 2026.
- Morgan Stanley held 35,198 shares of IGC Pharma worth $9.57K as of Q2 2026.
- Morgan Stanley bought 80 IGC Pharma shares in Q2 2026, an estimated $24.
- IGC Pharma made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #7057 holding.
- Morgan Stanley first reported a position in IGC Pharma in Q2 2013 and has held it in 32 quarters since.
- Morgan Stanley's IGC Pharma position peaked at $63K in Q1 2019.
- 36 funds tracked by Wall St. Rank held IGC Pharma as of Q2 2026.
Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.